Pharvaris N.V. – NASDAQ:PHVS
Pharvaris N.V. stock price today
$23.26
+3.83
+19.71%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Pharvaris N.V. stock price monthly change
+3.52%
month
Pharvaris N.V. stock price quarterly change
+3.52%
quarter
Pharvaris N.V. stock price yearly change
-28.64%
year
Pharvaris N.V. key metrics
Market Cap | 1.04B |
Enterprise value | 89.64M |
P/E | -5.12 |
EV/Sales | N/A |
EV/EBITDA | -1.83 |
Price/Sales | N/A |
Price/Book | 1.31 |
PEG ratio | 0.07 |
EPS | -2.34 |
Revenue | N/A |
EBITDA | -84.80M |
Income | -82.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePharvaris N.V. stock price history
Pharvaris N.V. stock forecast
Pharvaris N.V. financial statements
Average Price Target
$42
Potential upside: 80.56%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | 733.07K | |
|---|---|---|---|
| Sep 2023 | 0 | -23.59M | |
| Dec 2023 | 0 | -31.90M | |
| Mar 2024 | 0 | -28.01M |
| Jun 2023 | 189743422 | 16.01M | 8.44% |
|---|---|---|---|
| Sep 2023 | 169339425 | 16.21M | 9.57% |
| Dec 2023 | 399023176 | 14.65M | 3.67% |
| Mar 2024 | 377595207 | 18.42M | 4.88% |
| Jun 2023 | -20.48M | -35.07K | 63.84M |
|---|---|---|---|
| Sep 2023 | -23.55M | -7.49K | -122.33K |
| Dec 2023 | -22.41M | -26.95K | 254.29M |
| Mar 2024 | -24.23M | -30.70K | 795.04K |
Pharvaris N.V. alternative data
| Sep 2023 | 68 |
|---|---|
| Oct 2023 | 68 |
| Nov 2023 | 68 |
| Dec 2023 | 70 |
| Jan 2024 | 70 |
| Feb 2024 | 70 |
| Mar 2024 | 70 |
| Apr 2024 | 70 |
| May 2024 | 82 |
| Jun 2024 | 83 |
| Jul 2024 | 83 |
Pharvaris N.V. other data
20.32%
-43.11%
of PHVS is owned by hedge funds
6.82M
-14.47M
shares is hold by hedge funds
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis
Pharvaris: Focused Pipeline On Hereditary Angioedema
-
What's the price of Pharvaris N.V. stock today?
One share of Pharvaris N.V. stock can currently be purchased for approximately $23.26.
-
When is Pharvaris N.V.'s next earnings date?
Unfortunately, Pharvaris N.V.'s (PHVS) next earnings date is currently unknown.
-
Does Pharvaris N.V. pay dividends?
No, Pharvaris N.V. does not pay dividends.
-
How much money does Pharvaris N.V. make?
Pharvaris N.V. has a market capitalization of 1.04B.
-
What is Pharvaris N.V.'s stock symbol?
Pharvaris N.V. is traded on the NASDAQ under the ticker symbol "PHVS".
-
What is Pharvaris N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pharvaris N.V.?
Shares of Pharvaris N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Pharvaris N.V. have?
As Jul 2024, Pharvaris N.V. employs 83 workers, which is 19% more then previous quarter.
-
When Pharvaris N.V. went public?
Pharvaris N.V. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
-
What is Pharvaris N.V.'s official website?
The official website for Pharvaris N.V. is pharvaris.com.
-
How can i contact Pharvaris N.V.?
Pharvaris N.V. can be reached via phone at +31 71 203 6410.
-
What is Pharvaris N.V. stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Pharvaris N.V. in the last 12 months, the avarage price target is $42. The average price target represents a 80.56% change from the last price of $23.26.
Pharvaris N.V. company profile:
Pharvaris N.V.
pharvaris.comExchange:
NASDAQ
Full time employees:
83
Industry:
Biotechnology
Sector:
Healthcare
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
J.H. Oortweg 21
Leiden, 2333 CH
Leiden, 2333 CH
CIK: 0001830487
ISIN: NL00150005Y4
CUSIP: N69605108
